Nasdaq:CALC
CalciMedica, Inc.
A clinical-stage biopharmaceutical firm developing treatments for rare bone disorders, currently operating at a loss to fund R&D and asset acquisitions.
Key Metrics
Investment Thesis
Bull Case
Investors may view CALC as a high-risk, high-reward opportunity given its focus on unmet medical needs in rare bone diseases which could yield significant market share upon successful drug approval. The company's ability to secure $15.2M in financing and maintain positive cash flow from investing ($9.6M) suggests strong relationships with investors or asset buyers that provide necessary runway for clinical milestones. Potential catalysts include upcoming Phase 3 trial readouts or partnership agreements that could transform the current negative equity position into a valuable biotech asset.
Bear Case
The stock is highly speculative due to the lack of commercial revenue and a persistent net profit loss of -$29.6M which threatens long-term solvency against its $20.2M in total liabilities. The deteriorating financial trend with losses increasing from -$13.7M in 2024 back to -$29.6M in 2025 signals that current R&D spending is outpacing any potential value creation or financing inflows. With negative shareholders equity and no revenue, the company faces an existential risk if it cannot raise capital quickly enough to sustain its expensive research programs.
About CalciMedica, Inc.
CalciMedica (CALC) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat bone-related disorders and other conditions. The company primarily serves patients with rare diseases such as osteogenesis imperfecta, utilizing its proprietary technology platforms to advance drug candidates through preclinical and clinical development stages. Currently, the company operates without significant commercial revenue streams while relying heavily on financing activities to fund its extensive research and development efforts.
Analysis
Management Discussion
Despite a recent improvement in net loss from -$34.4M in 2023 to -$13.7M in 2024, the company reverted to a heavier deficit of -$29.6M in 2025, indicating ongoing high burn rates typical of clinical-stage development. The negative operating profit of -$23.1M and substantial general and administrative expenses suggest that the company is prioritizing asset accumulation and R&D over immediate profitability, utilizing its remaining cash reserves to fund these strategic initiatives.
Industry Overview
The biopharmaceutical industry for rare diseases is characterized by high failure rates, long development cycles, and significant regulatory hurdles before a product can reach commercialization. Companies in this space typically operate at substantial losses during the R&D phase, relying on venture capital or public markets to fund their pipeline until a drug receives FDA approval. Success in this sector depends heavily on proprietary technology and the ability to navigate complex clinical trial requirements for conditions like osteogenesis imperfecta.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $36.2M | $38.1M | $24.2M | $23.1M |
| Operating Income | $-36.2M | $-38.1M | $-24.2M | $-23.1M |
| R&D | $14.1M | $15.9M | $14.5M | $15.2M |
| G&A | $19.1M | $22.2M | $9.7M | $7.9M |
| Stock-Based Comp | $6.7M | $12.0M | $2.3M | $3.0M |
| D&A | — | $58.0K | — | — |
| Depreciation | $338.0K | $58.0K | $58.0K | $46.0K |
| Other OpEx | $3.0M | $-274.0K | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $-6.4M |
| Interest Income | $575.0K | — | — | — |
| Pre-Tax Income | $-36.2M | $-38.1M | $-24.2M | $-29.6M |
| Income Tax | $-575.0K | $1.0K | $0 | $0 |
| Continuing Ops | $-35.6M | $-38.1M | $-24.2M | $-29.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-35.6M | $-34.4M | $-13.7M | $-29.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-35.6M | $-34.4M | $-13.7M | $-29.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $39.7M | $11.6M | $19.7M | $13.5M |
| Cash & Equivalents | $17.3M | $5.5M | $7.9M | $11.5M |
| Marketable Securities | $21.8M | $5.7M | $10.7M | $1.5M |
| Prepaid Expenses | $542.0K | $367.0K | $248.0K | $259.0K |
| Other Current Assets | $0 | $0 | $748.0K | $255.0K |
| Long-Term Assets | $0 | $580.0K | $129.0K | $61.0K |
| PP&E (Net) | — | $167.0K | $119.0K | $50.0K |
| Operating Leases | — | $0 | — | — |
| Other LT Assets | — | $413.0K | $10.0K | $11.0K |
| Total Assets | $39.7M | $12.2M | $19.8M | $13.6M |
| Current Liabilities | $3.7M | $4.0M | $3.7M | $3.8M |
| Accounts Payable | $1.7M | $1.4M | $2.0M | $1.2M |
| Current Leases | $203.0K | — | — | — |
| Other Current Liab | $1.6M | $2.6M | $1.7M | $2.6M |
| Long-Term Liabilities | $0 | $0 | $1.7M | $16.4M |
| Total Liabilities | $3.7M | $4.0M | $5.4M | $20.2M |
| Shareholders' Equity | $36.0M | $8.2M | $14.4M | $-6.6M |
| Retained Earnings | $-204.8M | $-146.1M | $-159.8M | $-189.3M |
| AOCI | $-37.0K | $2.0K | $4.0K | $0 |
| Total L&E | $39.7M | $12.2M | $19.8M | $13.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-35.6M | $-34.4M | $-13.7M | $-29.6M |
| Non-Cash Adjustments | $13.8M | $11.9M | $-7.2M | $9.5M |
| Working Capital Changes | $-1.1M | $-3.3M | $-267.0K | $-1.2M |
| Cash from Operations | $-22.9M | $-25.7M | $-21.1M | $-21.2M |
| Capital Expenditures | $308.0K | $78.0K | $8.0K | $28.0K |
| Cash from Investing | $27.0M | $8.9M | $-4.4M | $9.6M |
| Cash from Financing | $-139.0K | $20.9M | $28.0M | $15.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $3.9M | $4.1M | $2.4M | $3.6M |
| Beginning Cash | $13.4M | $1.5M | $5.5M | $7.9M |
| Ending Cash | $17.3M | $5.5M | $7.9M | $11.5M |
Frequently Asked Questions
How does CalciMedica, Inc. make money?
The company's financial profile indicates a pure-play biopharmaceutical model with no current commercial revenue, relying entirely on cash flow from financing activities of $15.2M and common share issuances to fund operations. Key business activities include high-cost research and development ($15.2M in R&D expenses), administrative functions ($7.9M), and strategic investments such as the acquisition or purchase of assets reflected in cash flow from investing of $9.6M.
What are the main risks for CALC?
Significant operating losses including a net profit deficit of -$29.6M in the latest period which depletes the retained earnings deficit to -$189.3M; High dependency on external capital raising evidenced by heavy cash flow from financing ($15.2M) rather than operational profitability; Potential dilution risks from common share issuances and the company's negative shareholders equity of -$6.6M; Regulatory uncertainties in bringing novel bone disorder treatments to market.
What is CALC's competitive advantage?
Proprietary technology platforms for bone tissue engineering and regeneration; Access to rare disease patient populations that provide valuable data for clinical trials; Strategic financial flexibility demonstrated by a healthy cash position of $11.5M and significant non-cash adjustments ($9.5M) indicating potential asset restructuring or accounting optimizations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.